Day: 13 6 月, 2025

With the Department of Labour Peninsular Malaysia’s approval, the Ria Payroll Management System, coupled with the Ria Wallet and Prepaid Card Program, in collaboration with Mastercard, aims to promote financial inclusion among unbanked migrant workers throughout Malaysia, offering employers a secure and compliant way to manage their payroll needs.KUALA LUMPUR, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - Ria Money Transfer (“Ria”), a global leader in the cross-border money transfer industry and business segment of Euronet Worldwide, Inc. (NASDAQ: EEFT) has been officially approved by the Department of Labour Peninsular Malaysia (JTKSM) for the disbursement of digital wage payments via the Ria Wallet. By streamlining wage distribution through digital means, the Ria Prepaid Card Program, in collaboration with Mastercard, provides an omni-channel solution to employers who may struggle with conventional banking access for their workforce.The Ria Wallet facilitates various financial activities such as depositing funds, withdrawing cash from ATMs, paying bills, and conducting domestic and international transfers. Customers will also be able to make payments in millions of locations in Malaysia via QR payment linked to DuitNow. In addition, the Ria Wallet streamlines payroll management for Malaysia-based companies throughout industries heavily dependent on migrant workers, including construction, agriculture, and manufacturing.According to the International Organization of Migration (“IOM”), migrants represent an estimated 15.3% of Malaysia’s total workforce, many of whom are unbanked. The Ria Wallet addresses the challenges faced by both workers and employers in the country's cash-centric payment landscape.Ria’s presence in Malaysia since 2001 has positioned Ria as one of the leading players in the money transfer industry. Leveraging its strong physical network of 624,000 locations worldwide and its presence in nearly 200 countries and territories, Ria aims to provide a diverse and seamless service experience to all customers.Espen Kristensen, Ria Money Transfer’s Managing Director Asia Pacific, expressed his excitement for the expansion of Ria's service portfolio in Malaysia. He emphasized, “We understand the challenges employers in Malaysia face when it comes to managing wages for their workers. Through the Ria Wallet, companies will be able to benefit from a digital solution that improves transparency and compliance across their operations”.In collaboration with Mastercard, The Ria Prepaid Card Program underscores the company’s commitment to driving positive social impact through the financial empowerment of different communities worldwide. About Ria Money TransferRia Money Transfer, a business segment of Euronet (NASDAQ: EEFT), delivers innovative financial services including fast, secure, and affordable global money transfers. With the world’s largest cross border real-time money movement network, Ria moves money where it matters. Bridging the gap between digital and physical spaces, Ria’s omnichannel products and services provide unprecedented consumer choice, including real-time payments, mobile wallets, currency exchange, home delivery, and cardless ATM payouts. Ria’s global infrastructure, powered by the Dandelion real-time, cross-border payments network, facilitates financial access to customers, agents and partners alike. By creating new market opportunities and promoting economic growth around the world, Ria opens ways for a better everyday life. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE / INDIA, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - Asia Research & Engagement (ARE), a leading sustainability-focused consultancy and capital markets engagement firm, has expanded its India team with two senior appointments: Shishir Soti, Director, Global Operations and Partnerships and Arun Kumar, Strategic Advisor – Power Markets and Technology Innovation.Founded in 2013 and headquartered in Singapore, ARE works across Asia’s key economies – including China, India, and Japan – to drive sustainability outcomes through the alignment of capital markets, corporate strategy, and policy. India’s expanding influence in energy, agriculture, and capital markets makes it not just a domestic focus but a regional anchor for accelerating Asia’s net-zero transition.“India is already making bold strides on its decarbonisation journey,” said Benjamin McCarron, Founder & Managing Director, ARE. “Expanding our footprint here strengthens our ability to connect investor expectations and corporate ambition across the region, from Tokyo to Bangkok to Singapore. India’s scale and innovation are pivotal to designing future-fit systems across all of Asia.”Shishir Soti brings more than 25 years of experience to ARE, having held senior positions in banking and financial services at institutions including Standard Chartered and ICICI Bank, as well as senior roles at environmental groups such as the Shakti Sustainable Energy Foundation and Environmental Defense Fund. At ARE he will help deepen the integration of India into ARE’s regional programmes on financed emissions, sustainable food systems, and transition financing. He will also spearhead stakeholder engagement and fundraising strategy for ARE’s India programmes, advancing efforts to align Indian corporates and banks with net-zero goals.“India’s ambition to reach net-zero by 2070 has implications far beyond its borders,” said Soti. “Its energy and agricultural transitions will shape supply chains, investment flows, and climate ambition throughout Asia. I’m proud to support ARE’s work connecting policy, capital, and corporate action at this critical intersection.”Arun Kumar joins ARE with more than 25 years of experience in power markets, technology, and strategy, having held leadership positions at PTC India, HSBC Securities, KPMG and CRISIL where he was consistently ranked among India’s top energy analysts. He will provide strategic insights into regulatory trends, market innovation, and grid decarbonisation.“ARE’s investor-informed approach has already helped shift conversations in China, Japan, and Southeast Asia,” said Kumar. “India’s power market is on the cusp of transformation, and I look forward to helping shape the trajectory through collaborative engagement and technology foresight.”Soti and Kumar will work closely with Rituj Sahu, Director – Protein Transition (India), who has been leading ARE’s work on food systems, climate finance, and impact stewardship in India since 2022. Their collective expertise positions ARE to deepen its regional impact across three core pillars: Energy transition and financed emissions engagement with corporates and banks; Sustainable food and agriculture systems, with a focus on the protein transition; Capital mobilisation, bridging global finance with local sustainability outcomes.The India expansion complements and strengthens ARE’s ongoing work in Singapore, China, Taiwan, Japan, and Thailand – creating a more connected and coordinated platform for sustainable transformation across Asia.“To solve regional sustainability challenges, we need local intelligence, regional coordination, and global capital alignment,” added McCarron. “India is integral to the systems change ARE is driving across the region.”About Asia Research & Engagement (ARE)Creating change through investor-backed engagement. ARE's pioneering approach fills an engagement gap to bring leading investors into dialogue with Asian-listed companies. ARE currently works with investors representing US$10trillion. ARE covers Asian-listed companies from the financial sector, energy-related industries, and food value chains, seeking to advance a sustainable and compassionate Asia.For media interviews and further enquiries, please contactWani DiwakarAsia Research & Engagement (ARE) wani.diwarkar@asiareengage.com Copyright 2025 ACN Newswire via SeaPRwire.com.

KEY HIGHLIGHTS- Revenue up by 20.7% to HK$782.3 million- Gross profit increased by 22.4% to HK$413.7 million- Consolidated profit attributable to equity shareholders grew by 51.2% to HK$197.3 million- The Board recommends a final dividend of HK11.5 cents per share- Flagship proprietary brands Ho Chai Kung, Po Chai Pills, and Flying Eagle Woodlok Oil delivered robust growth through effective brand management campaigns- Concentrated Chinese medicine granules (“CCMG”) remained resilient, providing a steady contribution to overall business performanceHONG KONG, Jun 12, 2025 - (ACN Newswire via SeaPRwire.com) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the "Group"), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the annual results of the Group for the year ended 31 March 2025 ("FY2025" or the "Reporting Period").Despite a lackluster retail environment in Hong Kong, JBM Healthcare delivered a robust financial and operational performance in FY2025. Revenue from the branded healthcare business rose by 20.7% year-on-year to HK$782.3 million. Gross profit grew by 22.4% to HK$413.7 million, while consolidated profit attributable to equity shareholders surged 51.2% to HK$197.3 million.This significant increase in consolidated profit attributable to equity shareholders was driven by robust sales of flagship brands - including Ho Chai Kung, Po Chai pills, and Flying Eagle Woodlok Oil, complemented by the resilient performance of its CCMG business. These strong results underscore the effective execution of the Group’s integrated sales and marketing strategies, and its strategic foresight in capturing growth opportunities in the branded consumer healthcare market across Hong Kong, Macau, and major cities in the Greater Bay Area.The Board recommends a final dividend of HK11.5 cents per share. Including the interim dividend of HK5.5 cents per share already paid, the total dividend for FY2025 will be HK17.0 cents per share.Solid Performance Across Core SegmentsIn the branded medicines business, sales revenue recorded strong growth of 43.2%, propelled by Ho Chai Kung’s sustained market momentum. Ho Chai Kung successfully expanded its market penetration through precisely targeted marketing initiatives that broadened its consumer base while simultaneously reinforcing brand recognition.Sales in the proprietary Chinese medicines segment grew by 5.0% against the backdrop of softened local retail sentiment of Chinese medicines and herbs, driven by the momentum of flagship brands Po Chai Pills and Flying Eagle Woodlok Oil, alongside the resilient performance of the CCMG business. Po Chai Pills enhanced brand visibility through sustained TVC placements and title sponsorship of popular television programs. Meanwhile, Flying Eagle Woodlok Oil reinforced its market position with an integrated campaign themed “Flying Eagle – The Real Master’s Choice”, highlighted by a viral “Flying Eagle Bro” billboard at Tsim Sha Tsui Star Ferry Pier, which tripled brand awareness.In the health and wellness products segment, revenue increased by 44.9%, driven by the steady growth of Oncotype DX Breast Recurrence Score Test (“Oncotype DX”), along with the expansion of our product portfolio and enhanced marketing efforts to meet consumer healthcare demands of the mass market. Oncotype DX has gained increasing recognition among healthcare professionals in Hong Kong and Macau.Capturing the Growth Potential of Cross-Border E-Commerce and TCM SectorThe Group has made steady progress in expanding its online presence on cross-border e-commerce platforms as well as strategically positioned to capitalise on the growing traditional Chinese medicine (“TCM”) sector in Hong Kong and the Greater Bay Area. The Group’s flagship stores on Tmall Global and JD.com have performed strongly, with Ho Chai Kung ranking among the top 10 overseas medicines during the 2024 Double 11 sales event. To drive sustainable growth, the Group is also diversifying into new categories while enhancing both its B2B and B2C sales networks.Strategic Acquisition of Tin Hee TongIn April 2025, the Group completed the acquisition of a 90% stake in Tin Hee Tong Medicine Factory, Limited, whose flagship product, Tin Hee Tong Tin Hee Pills, is a well-recognised brand in Hong Kong and mainland China, particularly among female consumers for its efficacy in regulating the menstrual cycle and supporting reproductive health. The acquisition expands the Group’s proprietary Chinese medicine portfolio and creates synergies by integrating Tin Hee Tong’s brand with the Group’s manufacturing and marketing strengths. Leveraging its expertise in brand management, the Group will launch a comprehensive marketing campaign to boost awareness, enhance engagement, and broaden distribution.Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, commented, “Amid the challenging retail environment, we delivered strong financial and operational performance, driven by our robust portfolio, the enduring appeal of our flagship brands, and our unwavering focus on operational excellence.”“Looking ahead, we remain committed to disciplined growth and operational excellence. With rising health awareness, increasingly sedentary lifestyles, and an ageing population continuing to fuel demand, we are well-positioned to capitalise on growth opportunities in the consumer healthcare sector. We will continue to sharpen our brand management capabilities, strengthen our core brand equity, expand our product offerings, and extend our market reach.”About JBM (Healthcare) Limited (Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Tin Hee Tong Tin Hee Pills, Flying Eagle Woodlok Oil), Tong Tai Chung Woodlok Oil, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

业绩亮点- 收益增长20.7%至7.8亿港元- 毛利上升22.4%至4.1亿港元- 权益持有人应占综合溢利增长51.2%至1.97亿港元- 董事会建议派发末期股息每股11.5港仙- 凭借有效的品牌管理，旗舰品牌何济公、保济丸和飞鹰活络油实现强劲增长- 浓缩中药颗粒业务表现强韧，为整体业务表现提供稳定贡献香港，2025年6月12日 - (亚太商讯 via SeaPRwire.com) - 健倍苗苗（保健）有限公司（「健倍苗苗」或「公司」；股份代号：2161，连同其附属公司统称「集团」）为香港品牌保健品的领先营销商及分销商，集团今天公布截至二零二五年三月三十一日止年度（「二零二五财年」或「报告期」）的全年业绩。尽管香港零售环境疲软，健倍苗苗于二零二五财年的财务与营运表现仍然出色。集团品牌医疗保健业务的收益按年增长20.7%至7.8亿港元。毛利增长22.4%至4.1亿港元，权益持有人应占综合溢利飙升51.2%至1.97亿港元。权益持有人应占综合溢利大幅增长主要来自旗舰品牌的强劲销售表现，当中包括何济公、保济丸与飞鹰活络油，以及浓缩中药颗粒业务的稳健表现。这一优异表现，显示本集团成功落实整合的线上与线下营销策略，并体现集团的前瞻性市场触角，有效地把握香港、澳门及大湾区主要城市品牌消费健康市场增长机遇。董事会建议派发末期股息每股11.5港仙。包括已派付的中期股息每股5.5港仙，二零二五财年的股息总额为每股17.0港仙。各个核心业务表现卓越在何济公持续销售势头的带动下，品牌药分部的收益录得43.2%的强劲增长。何济公透过精准的市场营销计划扩大市场渗透率，成功扩大消费群体，同时进一步巩固品牌的知名度。在本港中成药及中药材的零售销售放缓的背景下，集团的品牌中药分部仍实现5.0%的增长。此增长主要来自旗舰品牌保济丸及飞鹰活络油的强劲表现，以及浓缩中药颗粒业务的稳健支持。保济丸通过持续的电视广告投放和冠名赞助电视人气节目，进一步提高品牌知名度。与此同时，飞鹰活络油透过以「飞鹰至系真王道」为主题的宣传计划强化市场地位，使其品牌知名度提升三倍，当中位于尖沙咀天星码头的「飞鹰哥」广告板更成功引起热议，迅速在网上疯传。健康保健品分部的销售收益增长44.9%，动力来自安可待乳癌肿瘤基因检测 (「Oncotype DX」)的稳健表现，加上产品组合扩展及加强推广，有效回应大众对健康产品日益增长的需求。Oncotype DX日益受到香港及澳门的医疗机构及医护专业人士的认可。把握跨境电子商务及中医药市场的增长潜力集团在拓展线上业务方面取得稳步进展，尤其是跨境电子商务平台，同时策略性地进行部署，把握香港及大湾区持续增长的传统中药行业机遇。集团在天猫国际和京东的旗舰店表现强劲，何济公于2024年双11期间位列十大海外药品畅销榜。为了推动可持续增长，集团正丰富多元化产品组合，同时加强B2B和B2C的销售网络。策略性收购天喜堂二零二五年四月，集团完成收购天喜堂药厂有限公司90%的股权，其旗舰产品「天喜堂天喜丸」于香港及中国内地享有极高的品牌知名度，特别受到女性消费者青睐，因其在调节女性生理周期及促进生殖健康方面具显著功效。这项收购进一步丰富了集团的品牌中药产品组合，并透过整合天喜堂品牌与集团现有的生产与营销能力，创造显著的协同效应。集团将凭借在品牌推广方面的丰富经验，开展全方位的市场推广计划，以提升该品牌知名度，加强与消费者的互动，以及扩展分销网络，进一步拓展客户基础。健倍苗苗行政总裁黄一伟先生表示：「面对零售环境的种种挑战，我们依然交出亮丽的财务及营运成绩，这有赖于我们多元而稳健的产品组合、旗舰品牌持久的市场吸引力，以及我们对卓越营运的不懈追求。展望未来，我们将继续秉持稳健增长与卓越营运的原则。随着健康意识提升、久坐的生活模式普及以及人口老龄化持续带动需求，我们已做好充分准备把握消费保健行业的增长机遇。我们将持续强化品牌管理能力，巩固核心品牌价值，扩展产品组合，并扩大市场覆盖范围。」有关健倍苗苗（保健）有限公司 （股份代号：2161）健倍苗苗是设于香港的品牌医疗保健品推广及分销公司，产品据点遍及大中华、东南亚及其他选定国家。集团拥有丰富的行销专业知识并具备深厚的制药背景，秉承产品功效和品质至上的优良传统，在行业内定位独特，致力于满足消费者的保健需要。作为本地领先的品牌医疗保健品运营商，集团拥有一广泛系列品牌医疗保健品，包括品牌药、品牌中药及健康保健品，其中包括「保济丸」、「何济公止痛退热散」、「天喜堂天喜丸」、「飞鹰活络油」、「唐太宗活络油」、「十灵油」、「镇痛霸祛风活络油」等家喻户晓的传统品牌。而自2021年 5月27日，集团获纳入 MSCI 香港微型股指数成份股。有关集团详情，请浏览：www.jbmhealthcare.com.hk Copyright 2025 亚太商讯 via SeaPRwire.com.